Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

NCT05833984 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

309

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor
Classic Hodgkin Lymphoma

Interventions

DRUG: IMM01
DRUG: Tislelizumab

Sponsor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.